To include your compound in the COVID-19 Resource Center, submit it here.

Nabi delays Altastaph program

NABI said that despite meeting the primary endpoints of safety and pharmacokinetics in a Phase II trial, the

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE